Development of new thiazolidine-2,4-dione hybrids as aldose reductase inhibitors endowed with antihyperglycaemic activity: design, synthesis, biological investigations, and
<i>in silico</i>
insights
作者:Abdelrahman Hamdi、Muhammad Yaseen、Wafaa A. Ewes、Mashooq Ahmad Bhat、Noha I. Ziedan、Hamed W. El-Shafey、Ahmed A. B. Mohamed、Mohamed R. Elnagar、Abdullah Haikal、Dina I. A. Othman、Abdullah A. Elgazar、Ahmed H. A. Abusabaa、Kamal S. Abdelrahman、Osama M. Soltan、Mostafa M. Elbadawi
DOI:10.1080/14756366.2023.2231170
日期:2023.12.31
Abstract This research study describes the development of new small molecules based on 2,4-thiazolidinedione (2,4-TZD) and their aldose reductase (AR) inhibitory activities. The synthesis of 17 new derivatives of 2,4-TZDs hybrids was feasible by incorporating two known bioactive scaffolds, benzothiazole heterocycle, and nitro phenacyl moiety. The most active hybrid (8b) was found to inhibit AR in a
摘要 这项研究描述了基于 2,4-噻唑烷二酮 (2,4-TZD) 的新型小分子的开发及其醛糖还原酶 (AR) 抑制活性。通过结合两种已知的生物活性支架、苯并噻唑杂环和硝基苯甲酰基部分,可以合成 17 种新的 2,4-TZD 杂化衍生物。动力学研究和分子对接模拟证实,最活跃的杂交体 ( 8b ) 以非竞争性方式 (0.16 µM) 抑制 AR。此外,体内实验表明,化合物8b对链脲佐菌素诱导的高血糖小鼠具有显着的降血糖作用。每公斤50毫克的8b剂量可显着降低血糖浓度,而5毫克/公斤的较低剂量则显示出明显的降血糖作用。这些结果表明化合物8b可用作治疗糖尿病并发症的有前途的治疗剂。